贝伐珠单抗联合化疗对非小细胞肺癌患者免疫功能及生活质量的影响

Effect of Bevacizumab Combined with Chemotherapy on Immune Function and Quality of Life in Patients with Non-small Cell Lung Cancer

目的:探讨贝伐珠单抗联合化疗对非小细胞肺癌(NSCLC)患者免疫功能及生活质量的影响。方法:选择2017年11月-2020年1月就诊于本院的90例NSCLC患者。按随机数字表法将患者分为观察组和对照组,各45例。对照组行常规GP化疗方案治疗,观察组在对照组基础上加用贝伐珠单抗注射液治疗。比较两组临床疗效、免疫功能、生活质量、不良反应发生情况。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)均高于对照组,差异均有统计学意义(P<0.05)。治疗后,两组KPS评分均高于治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05)。观察组血小板减少、肝功能损害、恶心/呕吐发生率均低于对照组,差异均有统计学意义(P<0.05);两组白细胞减少、骨髓抑制发生率比较,差异均无统计学意义(P>0.05)。结论:贝伐珠单抗联合化疗治疗NSCLC患者能够有效控制肿瘤生长,提高免疫功能和生活质量,减少不良反应发生,安全性较高。

Objective:To investigate the effects of Bevacizumab combined with chemotherapy on immune function and quality of life in patients with non-small cell lung cancer (NSCLC).Method:A total of 90 patients with NSCLC admitted to our hospital from November 2017 to January 2020 were selected.The patients were divided into observation group and control group by random number table method,45 cases in each group.The control group received conventional GP chemotherapy,the observation group was treated with Bevacizumab Injection on the basis of the control group.Clinical efficacy,immune function,quality of life and the occurrence of adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant (P<0.05).After treatment,CD3^(+),CD4^(+),CD8^(+) and CD4^(+)/CD8^(+) in the observation group were higher than those in the control group,the differences were statistically significant (P<0.05).After treatment,KPS scores in both groups were higher than those before treatment,and the observation group was higher than that of the control group,the differences were statistically significant (P<0.05).The incidence of thrombocytopenia,liver function damage and nausea/vomiting in the observation group were lower than those in the control group,the differences were statistically significant (P<0.05).The incidence of leukopenia and bone marrow suppression were compared between the two groups,there were no significant differences (P>0.05).Conclusion:Bevacizumab combined with chemotherapy in the treatment of NSCLC patients can effectively control tumor growth,improve immune function and quality of life,reduce adverse reactions and have high safety.